Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of “aged” people with cystic fibrosis
Therapeutic Advances in Respiratory Disease
Published online on January 03, 2026
Abstract
Therapeutic Advances in Respiratory Disease, Volume 20, January-December 2026.
Background:Therapeutic advancements utilizing modulators of the cystic fibrosis transmembrane conductance regulator (CFTR) have revolutionized the treatment of people with cystic fibrosis (pwCF). Elexacaftor-Tezacaftor-Ivacaftor (ETI) is a highly ...
Background:Therapeutic advancements utilizing modulators of the cystic fibrosis transmembrane conductance regulator (CFTR) have revolutionized the treatment of people with cystic fibrosis (pwCF). Elexacaftor-Tezacaftor-Ivacaftor (ETI) is a highly ...